CANCER GENETICS, INC Business Finance Contracts & Agreements
101 Contracts & Agreements
- Credit Agreements (14 contracts)
- Equity Distribution Agreements (1)
- Investor Rights Agreements (2)
- Loan Agreements (8)
- Note Agreements (12)
- Purchase Agreements (13)
- Registration Rights Agreements (6)
- Security Agreements (3)
- Share Agreements (4)
- Stock Agreements (13)
- Underwriting Agreements (9)
- Warrant Agreements (16)
- Share Purchase Agreement, dated March 13, 2023, by and between Vyant Bio, Inc. and Sabine Brandt as trustee for the Brandt Family Trust (Filed With SEC on March 15, 2023)
- Share Purchase Agreement, dated December 30, 2022, by and between vivoPharm Pty, Ltd. and Sabine Brandt as trustee for the Brandt Family Trust (Filed With SEC on January 5, 2023)
- Equity Purchase Agreement, dated November 2, 2022 by and among Vyant Bio, Inc., Reaction Biology Corporation and vivoPharm Pty, Ltd (Filed With SEC on November 3, 2022)
- Equity Distribution Agreement, dated April 8, 2022, by and between Vyant Bio, Inc. and Canaccord Genuity LLC (Filed With SEC on April 11, 2022)
- Registration Rights Agreement dated March 28, 2022 between Lincoln Park Capital, LLC and Vyant Bio, Inc (Filed With SEC on March 30, 2022)
- Purchase Agreement dated March 28, 2022 between Lincoln Park Capital, LLC and Vyant Bio, Inc (Filed With SEC on March 30, 2022)
- Form of Stock Unit Award Agreement (Filed With SEC on April 5, 2021)
- Form of Nonqualified Stock Option Grant Agreement (Filed With SEC on April 5, 2021)
- Form of Exchange Warrant dated March 30, 2021 (Filed With SEC on April 5, 2021)
- Form of Securities Purchase Agreement, dated February 10, 2021 (Filed With SEC on February 16, 2021)
- Form of Registration Rights Agreement, dated January 28, 2021 (Filed With SEC on February 1, 2021)
- Form of Securities Purchase Agreement, dated January 28, 2021 (Filed With SEC on February 1, 2021)
- Form of Common Warrant (Filed With SEC on February 1, 2021)
- Form of Warrant Exchange and Amendment Agreement, dated as of November 20, 2020, by and between Cancer Genetics, Inc. and the Holders (Filed With SEC on November 20, 2020)
- Amended and Restated Underwriting Agreement, dated October 28, 2020, by and between Cancer Genetics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on November 2, 2020)
- Exhibit 10.1 Note Purchase Agreement with Atlas Sciences (Filed With SEC on October 25, 2019)
- Exhibit 4.1 Promissory Note with Atlas Sciences (Filed With SEC on October 25, 2019)
- Forbearance and Sixth Amendment to Amended and Restated Loan and Security Agreement, between Cancer Genetics, Inc. and Silicon Valley Bank, dated June 13, 2019 (Filed With SEC on August 19, 2019)
- Asset Purchase Agreement, dated July 5, 2019, by and among siParadigm, LLC and Cancer Genetics, Inc (Filed With SEC on August 19, 2019)
- Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
- Promissory Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)
- Forbearance Agreement and Modification No. 4 to Loan and Security Agreement with Partners for Growth IV, L.P., dated January 16, 2019 (Filed With SEC on January 16, 2019)
- Forbearance and Fifth Amendment to Amended and Restated Loan and Security Agreement with Silicon Valley Bank, dated January 16, 2019 (Filed With SEC on January 16, 2019)
- Underwriting Agreement, dated January 9, 2019, by and between Cancer Genetics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 10, 2019)
- Registration Rights Agreement, dated September 18, 2018, by and between Cancer Genetics, Inc. and NovellusDx Ltd (Filed With SEC on September 21, 2018)
- Promissory Note, dated September 18, 2018, in favor of NovellusDx Ltd (Filed With SEC on September 21, 2018)
- Credit Agreement, dated September 18, 2018, by and between Cancer Genetics, Inc. and NovellusDx Ltd (Filed With SEC on September 21, 2018)
- Exhibit 10.2 Waiver and Modification No. 3 to Loan and Security Agreement with Partners for Growth IV, L.P., dated as of August 20, 2018 (Filed With SEC on August 21, 2018)
- Exhibit 10.1 Waiver and Third Amendment to Amended and Restated Loan and Security Agreement with Silicon Valley Bank, dated as of August 20, 2018 (Filed With SEC on August 21, 2018)
- Securities Purchase Agreement (Filed With SEC on July 18, 2018)
- Convertible Promissory Note (Filed With SEC on July 18, 2018)
- Joinder and Modification No. 2 to Loan and Security Agreement with Partners for Growth IV, L.P., dated as of June 30, 2018 (Filed With SEC on July 5, 2018)
- Omnibus Warrant Amendment to Warrant Issued to Lenders, dated as of June 30, 2018 (Filed With SEC on July 5, 2018)
- Exhibit 10.1 Joinder and Second Amendment to Amended and Restated Loan and Security Agreement with Silicon Valley Bank, dated as of June 21, 2018 (Filed With SEC on June 27, 2018)
- Exhibit 10.1 Share Purchase Agreement dated April 26, 2018 by and among BioServe Biotechnologies (India) Private Limited, Cancer Genetics, Inc. and Reprocell Incorporated (Filed With SEC on April 27, 2018)
- Form of Securities Purchase Agreement, dated December 8, 2017, by and between Cancer Genetics, Inc. and various purchasers named therein (Filed With SEC on December 8, 2017)
- Form of Warrant Agreement of Cancer Genetics, Inc (Filed With SEC on December 8, 2017)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 16, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 16, 2017)
- STOCK PURCHASE AGREEMENT among VIVOPHARM PTY. LTD. BRANDT FAMILY TRUST SOUTH AUSTRALIAN LIFE SCIENCE ADVANCEMENT PARTNERSHIP, LP ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY MANAGEMENT... (Filed With SEC on August 16, 2017)
